Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy - Concepedia

Concepedia

Publication | Open Access

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

DOI Full Paper Access

598

Citations

21

References

2019

Year

Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar, Bradley A. McGregor, Elisabeth I. Heath, Evan Y. Yu, Matthew D. Galsky, Noah M. Hahn, Elaina M. Gartner, Juan Pinelli,

Journal of Clinical Oncology

Abstract

Enfortumab vedotin demonstrated a clinically meaningful response rate with a manageable and tolerable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum and anti-PD-1/L1 therapies.

References

	Year	Citations

Page 1